Get started
Author

Maria Maddalena Plazzi

Observed names: M M Plazzi, M Plazzi, M. Plazzi, M.M. Plazzi, Maria M. Plazzi, Maria Maddalena Piazzi
ORCID: 0000-0002-1574-1552
Observed ORCID: 0000-0002-1574-1552
OpenAlex ID: A5027361273
Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against SARS-CoV-2 in People Living with HIV (PLWH) Receiving Antiretroviral Therapy (ART) According with Current CD4 T-Lymphocyte Count
2021 · Andrea Antinori, Stefania Cicalini, et al. · Clinical Infectious Diseases · 152
PDF
Parvovirus B19 Clearance from Peripheral Blood after Acute Infection
1995 · M. Musiani, M. Zerbini, et al. · The Journal of Infectious Diseases · 123
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
2022 · Alessandra Vergori, Alessandro Cozzi Lepri, et al. · Nature Communications · 101
PDF
Declining Prevalence of Human Immunodeficiency Virus (HIV)–Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy–Treated Individuals With HIV
2022 · Ilaria Mastrorosa, Carmela Pinnetti, et al. · Clinical Infectious Diseases · 41
PDF
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study
2024 · Valentina Mazzotta, Alessandro Cozzi Lepri, et al. · EClinicalMedicine · 40
GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults
2021 · Simone Lanini, Stefania Capone, et al. · Science Translational Medicine · 34
PDF
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration
2024 · Erich Tusch, Lene Ryom, et al. · Clinical Infectious Diseases · 30
PDF
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
2025 · Roberta Gagliardini, Sara De Benedittis, et al. · Journal of Antimicrobial Chemotherapy · 22
Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection
2022 · Simone Lanini, Stefano Milleri, et al. · Nature Communications · 19
PDF
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort
2019 · Lucia Taramasso, Patrizia Lorenzini, et al. · Journal of Antimicrobial Chemotherapy · 18
PDF
Rapid ART initiation with bictegravir/emtricitabine/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study)
2023 · Marta Camici, Roberta Gagliardini, et al. · International Journal of Antimicrobial Agents · 17
Central nervous system penetration‐effectiveness rank does not reliably predict neurocognitive impairment in HIV‐infected individuals
2014 · Raffaella Libertone, Patrizia Lorenzini, et al. · Journal of the International AIDS Society · 16
PDF
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort
2024 · Antonella d’Arminio Monforte, Alessandro Tavelli, et al. · Journal of Antimicrobial Chemotherapy · 15
PDF
Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals
2017 · Gabriella Rozera, Gabriele Fabbri, et al. · PLoS ONE · 14
PDF
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015–21
2024 · Lavinia Fabeni, Daniele Armenia, et al. · Journal of Antimicrobial Chemotherapy · 13
PDF
Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH
2022 · Roberta Gagliardini, Alessandra Vergori, et al. · Journal of Clinical Medicine · 13
PDF
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART
2018 · Francesca Ceccherini-Silberstein, Alessandro Cozzi Lepri, et al. · Journal of Antimicrobial Chemotherapy · 12
PDF
Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study
2023 · Antonella D’arminio Monforte, Alessandro Tavelli, et al. · Journal of Antimicrobial Chemotherapy · 11
PDF
Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results
2022 · Chiara Agrati, Concetta Castilletti, et al. · npj Vaccines · 9
PDF
Serological screening for the prevention of transfusion-acquired cytomegalovirus infection
1984 · M. Musiani, M. Zerbini, et al. · Journal of Infection · 9
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort
2019 · Antonella d’Arminio Monforte, Alessandro Tavelli, et al. · Journal of Antimicrobial Chemotherapy · 8
PDF
Effectiveness and Tolerability of DOR/3TC/TDF in Experienced People with HIV Switching from RPV/FTC/TDF: A Retrospective, Single Center Cohort Study
2024 · Stefania Cicalini, Simone Lanini, et al. · Pharmaceuticals · 7
PDF
Molecular Transmission Dynamics of Primary HIV Infections in Lazio Region, Years 2013–2020
2021 · Lavinia Fabeni, Gabriella Rozera, et al. · Viruses · 7
PDF
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients
2020 · Vincenzo Malagnino, Carlotta Cerva, et al. · Open Forum Infectious Diseases · 7
PDF
Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study)
2022 · Ilaria Mastrorosa, Roberta Gagliardini, et al. · EClinicalMedicine · 6
Works count: 44
Citation count: 798
H-index: 14
I10-index: 19
Year
Topic
Type